Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Registration Number
- NCT04324125
- Lead Sponsor
- Hunan Province Tumor Hospital
- Brief Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
- Detailed Description
Main enrolled criteria:
Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- HER 2 Insertion or Amplification
- First Diagnosis and Treatment
- Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion Criteria
- Patients received antitumor treatment before
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS may 2020- may 2021 (1 year) Progression free survival
- Secondary Outcome Measures
Name Time Method ORR may 2020- may 2021 (1 year) To measure the patients's overall response rate
OS may 2020- may 2021 (1 year) Overall survival
Trial Locations
- Locations (1)
Yongchang Zhang
🇨🇳Changsha, Hunan, China